Regenxbio (RGNX) popped on the first trading day of its upsized initial public offering, which raised $138.6 million for the drugmaker. Regenxbio priced at 22 and opened at 30.26, up 38%, and remained near there in midday trading. It had previously set a price range of 17 to 19. The biotech company offered 6.3 million shares, above previous plans to offer 5.6 million shares. Regenxbio is focused on developing, commercializing and licensing
Regenxbio (RGNX) turned in a strong performance Wednesday, with an upsized initial public offering that raised $138.6 million. The biotech company priced 6.3 million shares, above previous plans to offer 5.6 million shares, at 22 a share. Its initial expected price range was 17 to 19. Research firm IPOboutique.com previously reported that the deal was “multiple times oversubscribed.” Regenexbio is focused on developing, commercializing and
Demand for Regenxbio (RGNX) stock is strong heading into the pricing of its initial public offering, scheduled to occur late Wednesday. Research firm IPOboutique.com says channel checks reveal, according to underwriter guidance, that the deal is now “multiple times oversubscribed.” Regenxbio plans to raise $122 million by offering 5.6 million shares at $22 each. It previously set a price range of 17 to 19. The biotech company developing,